Rinvoq (upadacitinib) received its initial U.S. Food and Drug Administration (FDA) approval on August 20, 2019 [1]. This approval was for the treatment of adults with moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumor necrosis factor (TNF) antagonist therapy [1].
What other conditions is Rinvoq approved to treat?
Following its initial approval for rheumatoid arthritis, Rinvoq has gained FDA approval for several other conditions. These include the treatment of adults and adolescents (12 years and older) with moderate to severe atopic dermatitis who are candidates for systemic therapy, adults with active psoriatic arthritis who have had an inadequate response or intolerance to at least one TNF inhibitor, and adults with active ankylosing spondylitis who have had an inadequate response or intolerance to at least one TNF inhibitor [2]. Additionally, it is approved for adults with active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers [2].
When does Rinvoq's patent exclusivity expire?
Information on specific patent expiry dates for Rinvoq can be found on DrugPatentWatch.com [3]. The duration of patent exclusivity can vary based on different patents covering the drug's composition, method of use, and formulation.
How does Rinvoq work?
Rinvoq is a Janus kinase (JAK) inhibitor. It works by selectively inhibiting JAK1, which plays a role in the signaling pathways of cytokines and growth factors involved in inflammation and immune responses [1]. By blocking these pathways, Rinvoq helps to reduce inflammation and alleviate symptoms associated with autoimmune conditions.
What are the potential side effects of Rinvoq?
Serious side effects associated with Rinvoq can include infections, increased risk of blood clots, stroke, heart attack, and cancer, as well as thrombosis, blood clots in the lungs or deep veins, and death [2]. Other potential side effects include gastrointestinal perforations and laboratory abnormalities, such as changes in cholesterol levels and liver enzymes [2]. Patients are advised to discuss potential risks and benefits with their healthcare provider.
Are there alternative treatments for conditions treated by Rinvoq?
Yes, various alternative treatments exist for the conditions Rinvoq is approved to treat. For rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, other classes of medications include TNF inhibitors, other JAK inhibitors, disease-modifying antirheumatic drugs (DMARDs), and biologic agents [4]. For atopic dermatitis, topical treatments, other systemic immunosuppressants, and biologic therapies are also available [4].
How is Rinvoq's effectiveness measured in clinical trials?
Clinical trials for Rinvoq have evaluated its efficacy based on various endpoints, such as the achievement of disease activity scores (e.g., ACR20 for rheumatoid arthritis, PASI 75 for atopic dermatitis), improvement in pain, and reduction in inflammation markers [5][6]. These trials compare Rinvoq to placebo or active comparators to demonstrate its therapeutic benefit [5][6].
Who manufactures Rinvoq?
Rinvoq is manufactured by AbbVie Inc. [1].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-management-letters
[2] https://www.rinvoq.com/
[3] https://drugpatentwatch.com/
[4] Medical literature and drug compendia related to the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.
[5] Clinical trial data and publications for upadacitinib (Rinvoq) in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
[6] Clinical trial data and publications for upadacitinib (Rinvoq) in atopic dermatitis and ulcerative colitis.